Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.

van der Schoot JMS, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AMD, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JAC, Engelfriet M, Caval T, Bentlage AEH, Fransen MF, Nederend M, Leusen JHW, Heck AJR, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA.

Sci Adv. 2019 Aug 28;5(8):eaaw1822. doi: 10.1126/sciadv.aaw1822. eCollection 2019 Aug.

2.

A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function.

Kleinovink JW, Mezzanotte L, Zambito G, Fransen MF, Cruz LJ, Verbeek JS, Chan A, Ossendorp F, Löwik C.

Front Immunol. 2019 Jan 8;9:3097. doi: 10.3389/fimmu.2018.03097. eCollection 2018.

3.

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F.

JCI Insight. 2018 Dec 6;3(23). pii: 124507. doi: 10.1172/jci.insight.124507.

4.

High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.

Benonisson H, Sow HS, Breukel C, Claassens J, Brouwers C, Linssen MM, Fransen MF, Sluijter M, Ossendorp F, van Hall T, Verbeek JS.

J Immunol. 2018 Dec 15;201(12):3741-3749. doi: 10.4049/jimmunol.1800700. Epub 2018 Nov 5.

PMID:
30397036
5.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.

Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12.

PMID:
30259976
6.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Benonisson H, Sow HS, Breukel C, Claassens JWC, Brouwers C, Linssen MM, Redeker A, Fransen MF, van Hall T, Ossendorp F, Arens R, Verbeek S.

Oncotarget. 2018 Jun 29;9(50):29392-29402. doi: 10.18632/oncotarget.25630. eCollection 2018 Jun 29.

7.

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Fransen MF, Benonisson H, van Maren WW, Sow HS, Breukel C, Linssen MM, Claassens JWC, Brouwers C, van der Kaa J, Camps M, Kleinovink JW, Vonk KK, van Heiningen S, Klar N, van Beek L, van Harmelen V, Daxinger L, Nandakumar KS, Holmdahl R, Coward C, Lin Q, Hirose S, Salvatori D, van Hall T, van Kooten C, Mastroeni P, Ossendorp F, Verbeek JS.

J Immunol. 2018 Apr 15;200(8):2615-2626. doi: 10.4049/jimmunol.1700429. Epub 2018 Mar 9.

8.

Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells.

Kleinovink JW, Fransen MF, Löwik CW, Ossendorp F.

Cancer Immunol Res. 2017 Oct;5(10):832-838. doi: 10.1158/2326-6066.CIR-17-0055. Epub 2017 Aug 29.

9.

PD-L1 immune suppression in cancer: Tumor cells or host cells?

Kleinovink JW, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 May 12;6(7):e1325982. doi: 10.1080/2162402X.2017.1325982. eCollection 2017.

10.

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 Feb 21;6(4):e1294299. doi: 10.1080/2162402X.2017.1294299. eCollection 2017.

11.

Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.

Rad-Malekshahi M, Fransen MF, Krawczyk M, Mansourian M, Bourajjaj M, Chen J, Ossendorp F, Hennink WE, Mastrobattista E, Amidi M.

Mol Pharm. 2017 May 1;14(5):1482-1493. doi: 10.1021/acs.molpharmaceut.6b01003. Epub 2017 Jan 27.

12.

Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

Kleinovink JW, van Driel PB, Snoeks TJ, Prokopi N, Fransen MF, Cruz LJ, Mezzanotte L, Chan A, Löwik CW, Ossendorp F.

Clin Cancer Res. 2016 Mar 15;22(6):1459-68. doi: 10.1158/1078-0432.CCR-15-0515. Epub 2015 Nov 6.

13.

Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.

Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE.

Curr Pharm Des. 2015;21(29):4201-16. Review.

PMID:
26323429
14.

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE.

Biomaterials. 2015 Aug;61:33-40. doi: 10.1016/j.biomaterials.2015.04.043. Epub 2015 May 17.

PMID:
25993015
15.

Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.

Rahimian S, Fransen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE, Ossendorp F.

J Control Release. 2015 Apr 10;203:16-22. doi: 10.1016/j.jconrel.2015.02.006. Epub 2015 Feb 7.

PMID:
25660830
16.

Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response.

Rahimian S, Kleinovink JW, Fransen MF, Mezzanotte L, Gold H, Wisse P, Overkleeft H, Amidi M, Jiskoot W, Löwik CW, Ossendorp F, Hennink WE.

Biomaterials. 2015 Jan;37:469-77. doi: 10.1016/j.biomaterials.2014.10.043. Epub 2014 Oct 28.

PMID:
25453974
17.

IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation.

Quakkelaar ED, Fransen MF, van Maren WW, Vaneman J, Loof NM, van Heiningen SH, Verbeek JS, Ossendorp F, Melief CJ.

J Immunol. 2014 Jun 15;192(12):5813-20. doi: 10.4049/jimmunol.1302337. Epub 2014 May 9.

18.

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, Hennink WE, Melief CJ.

Vaccine. 2014 Mar 26;32(15):1654-60. doi: 10.1016/j.vaccine.2014.01.056. Epub 2014 Feb 7.

PMID:
24508038
19.

Local immunomodulation for cancer therapy: Providing treatment where needed.

Fransen MF, Ossendorp F, Arens R, Melief CJ.

Oncoimmunology. 2013 Nov 1;2(11):e26493. Epub 2013 Oct 10.

20.

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ.

Clin Cancer Res. 2013 Oct 1;19(19):5381-9. doi: 10.1158/1078-0432.CCR-12-0781. Epub 2013 Jun 20.

21.

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.

van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber WJ, Ossendorp F, Melief CJ, Arens R.

J Immunol. 2012 Oct 1;189(7):3397-403. Epub 2012 Aug 22.

22.

Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.

Fransen MF, Arens R, Melief CJ.

Int J Cancer. 2013 May 1;132(9):1971-6. doi: 10.1002/ijc.27755. Epub 2012 Aug 16. Review.

23.

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.

Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ.

Clin Cancer Res. 2011 Apr 15;17(8):2270-80. doi: 10.1158/1078-0432.CCR-10-2888. Epub 2011 Mar 9.

24.

Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formation.

Fransen MF, van Stipdonk MJ, Sluijter M, Schoenberger SP, Melief CJ, Offringa R.

J Immunol. 2010 Sep 15;185(6):3167-73. doi: 10.4049/jimmunol.0904046. Epub 2010 Aug 9.

25.

Maintenance of immune tolerance depends on normal tissue homeostasis.

Boonman ZF, van Mierlo GJ, Fransen MF, de Keizer RJ, Jager MJ, Melief CJ, Toes RE.

J Immunol. 2005 Oct 1;175(7):4247-54.

26.

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.

Cancer Res. 2005 Aug 1;65(15):6984-9.

27.

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ.

J Immunol. 2004 Dec 1;173(11):6753-9.

28.
29.

Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.

Boonman ZF, van Mierlo GJ, Fransen MF, Franken KL, Offringa R, Melief CJ, Jager MJ, Toes RE.

J Immunol. 2004 Feb 1;172(3):1567-74.

30.

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. Epub 2002 Apr 2.

31.

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.

den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE.

J Immunol. 2001 Sep 1;167(5):2522-8.

Supplemental Content

Loading ...
Support Center